[1] Ruparelia N,Choudhury R.Inflammation and atherosclerosis:what is on the horizon [J].Heart Br Cardiac Soc,2020,106(1):80-85.
[2] Teixeira FCOB, Götte M.Involvement of syndecan-1 and heparanase in cancer and inflammation[J].Adv Exp Med Biol,2020,1221:97-135.
[3] Muhammad RS,Abu-Saleh N,Kinaneh S,et al.Heparanase inhibition attenuates atherosclerosis progression and liver steatosis in E0 mice[J].Atherosclerosis,2018,276:155-162.
[4] Rivara S,Milazzo FM,Giannini G.Heparanase:a rainbow pharmacological target associated to multiple pathologies including rare diseases[J].Future Med Chem,2016,8(6):647-680.
[5] Cassinelli G,Torri G,Naggi A.Non-anticoagulant heparins as heparanase inhibitors[J].Adv Exp Med Biol,2020,1221:493-522.
[6] Aldi S,Eriksson L,Kronqvist M,et al.Dual roles of heparanase in human carotid plaque calcification[J].Atherosclerosis,2019,283:127-136.
[7] Sieve I,Münster-Kühnel AK,Hilfiker-Kleiner D.Regulation and function of endothelial glycocalyx layer in vascular diseases[J].Vasc Pharmacol,2018,100:26-33.
[8] Talepoor AG, Fouladseresht H, Khosropanah S, et al.Immune-inflammation in atherosclerosis:a new twist in an old tale[J].Endocr Metab Immune Disord Drug Targets, 2020, 20(4):525-545.
[9] 徐斌, 石祥恩, 李敏, 等.乙酰肝素酶及新生血管在人颈动脉粥样硬化斑块中的表达[J].中国脑血管病杂志, 2019, 16(3):116-122.
[10] Gurbuz AS, Ozturk S, Efe SC, et al.Serum heparanase level is decreased in stable coronary artery disease[J].Med Princ Pract, 2019, 28(6):573-580.
[11] 王静, 吴婵, 周睿, 等.乙酰肝素酶对血管内皮细胞增殖、迁移及血管活性因子表达的影响[J].中国医药生物技术, 2018, 13(3):213-218.
[12] Gurbuz AS, Ozturk S, Efe SC, et al.Heparanase is a predictive marker for high thrombus burden in patients with ST-segment elevation myocardial infarction[J].Biomarkers, 2019, 24(6):600-606.
[13] Madonna R, De Caterina R.Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis[J].Vasc Pharmacol, 2014, 60(2):49-51.
[14] Cui H, Tan YX, Österholm C, et al.Heparanase expression upregulates platelet adhesion activity and thrombogenicity[J].Oncotarget, 2016, 7(26):39486-39496.
[15] Bayam E, Kalçk M, Gürbüz AS, et al.The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis[J].Thromb Res, 2018, 171:103-110.
[16] Wang FL, Pulinilkunnil T, Flibotte S, et al.Heparanase protects the heart against chemical or ischemia/reperfusion injury[J].J Mol Cell Cardiol, 2019, 131:29-40.
[17] Masola V, Bellin G, Vischini G, et al.Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury[J].Oncotarget, 2018, 9(90):36185-36201.
[18] Hammond E, Dredge K.Heparanase inhibition by pixatimod (PG545):basic aspects and future perspectives[J].Adv Exp Med Biol, 2020, 1221:539-565.
[19] Jia L, Ma ST.Recent advances in the discovery of heparanase inhibitors as anti-cancer agents[J].Eur J Med Chem, 2016, 121:209-220.
[20] Gurung AB, Laso A, Bhattacharjee A.Identification of potential drug-like molecules for inhibition of the inflammatory activity of cyclooxygenase-2[J].J Biomol Struct Dyn, 2020, 38(18):5293-5306.
[21] Wang Q, Shi G L, Teng Y, et al.Successful reduction of inflammatory responses and arachidonic acid-cyclooxygenase 2 pathway in human pulmonary artery endothelial cells by silencing adipocyte fatty acid-binding protein[J].J Inflamm Lond Engl, 2017, 14:8.
[22] Li L H, Li J, Yi J, et al.Dose-effect of irbesartan on cyclooxygenase-2 and matrix metalloproteinase-9 expression in rabbit atherosclerosis[J].J Cardiovasc Pharmacol, 2018, 71(2):82-94.
[23] Ferrer MD, Busquets-Cortés C, Capó X, et al.Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases[J].Curr Med Chem, 2019, 26(18):3225-3241.
[24] Song KY, Li LT, Sun GL, et al.microRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2[J].Exp Ther Med, 2018, 15(5):4557-4563.
[25] Liang X, Yang LX, Guo RW, et al.Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway[J].Exp Ther Med, 2017, 13(3):835-844.
[26] Zhang K, Kong J, Liu B, et al.Regulatory T cells suppress the expression of COX-2 in vulnerable plaque[J].Heart Vessels, 2020, 35(2):278-283.
[27] Pang L, Cai Y, Tang EHC, et al.Cox-2 inhibition protects against hypoxia/reoxygenation-induced cardiomyocyte apoptosis via Akt-dependent enhancement of iNOS expression[J].Oxidative Med Cell Longev, 2016, 2016:3453059.
[28] 贾丹, 张媛, 连鑫, 等.抑制COX-2表达对心肌缺血再灌注损伤过程中心肌细胞保护作用的研究[J].中国实验诊断学, 2020, 24(3):495-498.
[29] Ferrer MD, Busquets-Cortés C, Capó X, et al.Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases[J].Curr Med Chem, 2019, 26(18):3225-3241.
[30] Gawthorpe S, Brown JE, Arif M, et al.Heparanase and COX-2 expression as predictors of lymph node metastasis in large, high-grade breast tumors[J].Anticancer Res, 2014, 34(6):2797-2800.
[31] Zeng C, Chen L, Yang Z, et al.The close correlation between heparanase and COX-2 expression in lymphangiogenesis of cervical cancer[J].Med Oncol Northwood Lond Engl, 2014, 31(12):314.
